Go back

FEAM Forum Regenerative Medicine workshop, 27 Nov 2019 | SUMMARY REPORT NOW AVAILABLE


Regenerative Medicine is considered a novel frontier of medical research and represents an interdisciplinary field that applies engineering and life science principles to promote regeneration, potentially restoring diseased and injured tissues. Substantially, regenerative medicine comprises three main approaches: cell-based therapy, use of engineered scaffolds and implantation of scaffolds seeded with cells. Since the onset of this field, a number of therapies have received Food and Drug Administration (FDA) approval and are now commercially available. In the last years, many scientific advances have been achieved such as the engineering of sophisticated grafts, bioartificial tissues and technologies for integrating grafts with host vasculature. However, there are still emerging needs and challenges to be faced in a global context related to either economic, political and scientific perspective as well as bioethical implications for Europe. In this context, the aim of this workshop was to provide a comprehensive overview on scientific advances, ongoing clinical trials, regulatory perspective, challenges and manufacturing of new drugs and products. Finally, the workshop proposed directions for effective future therapies.

Summary report
Watch the full event on the FEAM YouTube channel

About the FEAM European Biomedical Policy Forum

The FEAM European Biomedical Policy Forum provides a platform for discussion on key policy issues for the biomedical community.

The Forum is an initiative from the Federation of European Academies of Medicine (FEAM). It aims to bring together representatives from academia, research charities, industry, European and national trade associations and professional bodies, regulators, public health bodies, and patient and consumers groups. If you would like further information on the FEAM European Biomedical Policy Forum or becoming a partner, please contact elisa.corritore@feam.eu.

Subscribe to our newsletter